YLYong Liao

Yong Liao

*This is an algorithmically generated author record based on publicly available information.

Yong Liao has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Anliang Huang

    Department of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

    2 shared publications
  • Dengxiang Liu

    Xingtai Key Laboratory of Precision Medicine for Liver Cirrhosis and Portal Hypertension, Xingtai People’s Hospital of Hebei Medical University, Xingtai, People’s Republic of China

    2 shared publications
  • Hongrui Miao

    Department of Hepatobiliary Surgery, Tongji Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, Hubei, China

    2 shared publications
  • Jinlong Li

    Xingtai Key Laboratory of Precision Medicine for Liver Cirrhosis and Portal Hypertension, Xingtai People’s Hospital, Xingtai, Hebei, China

    2 shared publications
  • Xiaolong Qi

    Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Nanjing, China

    2 shared publications
  • Zhanguo Zhang

    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    2 shared publications

Latest Publications

  • Open Access

    Machine Learning-Accelerated Vascular Reconstruction for Rapid CFD-Based Hemodynamic Analysis via Composite Score-Driven Centerline Optimization

    by Tong Zhang, Yong Liao, Yongjian Li, Zujie Gao, Derong Qiu, Lin Zh, Timothy Shao Ern Tan, Haosheng Chen

    Background and Objectives: Reconstructing three-dimensional vascular models for computational fluid dynamics (CFD) is time-consuming, limiting clinical application. Conventional centerline-based approaches generate redundant control points, reducing efficiency. We propose a machine learning-accelerated framework for rapid vascular reconstruction via centerline optimization.Methods: A surrogate neural network predicts the Dice similarity coefficient (DSC) for fast estimation of volumetric overlap. A composite score (CS) balancing geometric fidelity and data reduction guides optimal threshold selection.Results: The method achieves >500-fold computation time reduction while maintaining high accuracy. In an abdominal aortic network, control points were reduced by 70% with DSC = 0.8698. CFD simulations confirm hemodynamic consistency with original models.Conclusions: This approach provides an efficient, scalable solution for generating CFD-ready vascular models, with potential for clinical decision-making and interventional planning.

  • Open Access

    Yttrium-90 Selective Internal Radiation Therapy for Right Hepatic Malignancies: A Clinical Outcome Study

    by Xin Huang, Yong Liao, Ziwei Liang, Junpeng Ma, Bin Liang, Shizhong Yang, Guangxin Li, Tiantian Zhang, Linxia Zheng, Yafei Zhang, et al.

    Background: Surgical resection offers long-term survival for liver malignancies, but insufficient future liver remnant (FLR) volume often precludes operability. This study evaluated yttrium-90 selective internal radiation therapy (90Y-SIRT) for controlling right-liver tumors and inducing compensatory left-lobe hyperplasia. Results: Thirty-seven patients (29 hepatocellular carcinomas, 2 intrahepatic cholangiocarcinoma, 6 liver metastasis of colorectal cancer) with right-liver tumors underwent 90Y-SIRT. Tumor volume decreased significantly by 133 mL at 1 month and 206 mL at 3 months post-treatment (both P90Y-SIRT effectively controls right-lobe tumor progression and stimulates compensatory left-lobe hypertrophy, enabling FLR expansion. The treatment achieved high ORR, significant tumor downstaging, and pathological necrosis without compromising hepatic functional reserve. Conclusions: 90Y-SIRT represents a safe and efficacious strategy to convert initially unresectable patients into surgical candidates.

  • Open Access

    Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

    by Jitao Wang, Tianlei Zheng, Yong Liao, Shi Geng, Jinlong Li, Zhanguo Zhang, Dong Shang, Chengyu Liu, Peng Yu, Yifei Huang, et al.

    Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study

  • Open Access

    A Novel Nomogram for Prediction of Post-Hepatectomy Liver Failure in Patients with Resectable Hepatocellular Carcinoma: A Multicenter Study

    by Jitao Wang, Zhanguo Zhang, Dong Shang, Yong Liao, Peng Yu, Jinling Li, Shubo Chen, Dengxiang Liu, Hongrui Miao, Shuang Li, et al.

    Objective: To develop a nomogram for predicting post-hepatectomy liver failure (PHLF) in patients with resectable hepatocellular carcinoma (HCC) based on portal hypertension, the extent of resection, ALT, total bilirubin, and platelet count. Methods: Patients with HCC hospitalized from January 2015 to December 2020 were included in a retrospective cohort study. 595 HCC patients were divided into a training cohort (n=416) and a validation cohort (n=179) by random sampling. Univariate and multivariable analyses were performed to identify the independent variables to predict PHLF. The nomogram models for predicting the overall risk of PHLF and the risk of PHLF B+C were constructed based on the independent variables. Comparisons were made by using receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) with traditional models, such as FIB-4 score, APRI score, CP class (Child-Pugh), MELD score (model of end-stage liver disease), and ALBI score (albumin-bilirubin) to analyze the accuracy and superiority of the nomogram. Results: We discovered that portal hypertension (yes vs no) (OR=1.677,95% CI:1.817– 4.083, p=0.002), the extent of liver resection (OR=1.872,95% CI:3.937– 47.096, p=0.001), ALT (OR=1.003,95% CI:1.003– 1.016, P=0.003), total bilirubin (OR=1.036,95% CI:1.031– 1.184, p=0.005), and platelet count (OR= 1.004, 95% CI:0.982– 0.998, p=0.020) were independent risk factors for PHLF using multifactorial analysis. The nomogram models were constructed using well-fit calibration curves for each of these five covariates. When compared to the FIB4, ALBI, MELD, and CP score, our nomogram models have a better predictive value for predicting the overall risk of PHLF or the risk of PHLF B+C. The validation cohort’s results were consistent. DCA also confirmed the conclusion. Conclusion: Our models, in the form of static nomogram or web application, were developed to predict PHLF overall risk and PHLF B+C risk in patients with HCC, with a high prediction sensitivity and specificity performance than other commonly used scoring systems.


  • Open Access

    Downregulation of RRS1 Inhibits Proliferation, Migration, And Epithelial-Mesenchymal Transition In Hepatocellular Carcinoma

    by Zhi Li, Jitao Wang, Chengyu Liu, Jinlong Li, Xiaochong Zhang, Xiaoling Zhao, Kunpeng Zhang, Zhongguang Zhen, Dengxiang Liu, Yong Liao

    Background: Regulator of ribosome rynthesis 1 (RRS1) is an important nuclear protein involved in the biogenesis of ribosomes, and its relationship with a variety of cancers is confirmed by several studies. However, the underlying mechanism of RRS1-related carcinogenesis remains largely elusive.Methods: In this study, we aimed to investigated the role of RRS1 in hepatocellular carcinoma (HCC) by detecting the expression level of RRS1 in HCC tissues and para-carcinoma tissues and its effect on the proliferation, migration and epithelial-mesenchymal transition of HCC. Results: Compared with para-carcinoma tissues, the expression of RRS1 was significantly higher in HCC tissues, which is associated with the poor prognosis for HCC patients. In addition, knockdown RRS1 in HCC cell lines inhibited proliferation, migration and epithelial-mesenchymal transition (EMT). Conclusions: Our results indicated that RRS1 played an important role in proliferation, migration and EMT process of HCC. Hence, RRS1 might emerge as a promising therapeutic target for HCC.

  • Open Access

    Aberrant Kank1 expression regulates YAP to promote apoptosis and inhibit proliferation in OSCC

    by Hui Fan, Hao Tian, Xiang Cheng, Yanan Chen, Shoujian Liang, Zhenjian Zhang, Yong Liao, Pu Xu

    The kidney ankyrin repeat‐containing protein 1 (Kank1) gene is one of the most important members of the KANK family. Kank1 has hybridity deletion and promoter methylation in the cancer tissues of the brain, lung, kidney and the corresponding cell lines, leading to downregulation of the gene expression. Meanwhile, Kank1 also plays a key role in the occurrence and development of various types of tumors, suggesting that Kank1 may be an anti‐oncogene. However, its role and the potential mechanisms in the Oral Squamous Cell Carcinoma (OSCC) remain unclear. We examined the expression of Kank1 in OSCC tissues and explored its clinical significance. In addition, we investigated the effects of Kank1 on the biological behavior of OSCC cells and their specific molecular mechanisms. We found that Kank1 was poorly expressed in OSCC tissues and it is correlated with the OSCC stage and the patient's poor prognosis. By overexpression of Kank1, we found that the proliferation ability of the OSCC cells decreased both in vitro and in vivo, the proportion of apoptotic cells increased, and the mitochondrial transmembrane potential decreased. In terms of the molecular mechanism, we confirmed that Kank1 could inhibit the occurrence of OSCC by regulating Yap to inhibit the proliferation and promote apoptosis of the OSCC cells. Moreover, it was found that the overexpression of YAP reversed those effects caused by Kank1 overexpression on the OSCC cells. In conclusion, the research indicated that Kank1 might play an anti‐oncogenic role in OSCC and it could be considered to be a target for the diagnosis and the treatment of OSCC.